ASCO 2024: Bristol Myers Squibb’s Opdivo-Yervoy Combo Challenges Roche and AstraZeneca in First-Line Liver Cancer Treatment

1. Positive Phase III Data: Bristol Myers Squibb's Opdivo-Yervoy combination has shown positive results in the Phase III CheckMate-9DW trial for first-line treatment of unresectable liver cancer, potentially challenging existing treatments from Roche and AstraZeneca.
2. Survival Rate: The Opdivo-Yervoy combo demonstrated a median overall survival (OS) of 23.7 months, outperforming the control group's 20.6 months, which included patients treated with either Lenvima or Nexavar.
3. Risk Reduction: The combination reduced the risk of death by 21% compared to the control group, with a hazard ratio (HR) of 0.79 (p < 0.0001). 4. Comparison to Existing Treatments: The Opdivo-Yervoy combo's median OS of 23.7 months compares favorably to Roche's Tecentriq-Avastin combo (19.2 months) and AstraZeneca's Imfinzi-Imjudo combo (16.4 months), both of which were approved based on data against Nexavar. 5. Toxicity Concerns: The Opdivo-Yervoy regimen was associated with higher toxicity, with 13% of patients experiencing grade 3/4 treatment-related adverse events, compared to 6% in the control group. 6. Future Discussions: Bristol Myers Squibb plans to discuss the results with health authorities, potentially leading to approval for first-line liver cancer treatment.